JP Morgan: Raises installation forecast for Siasun Robot & Automation-W (02252) and target price to 42 Hong Kong dollars.

JPMorgan Chase released a research report stating that the target price for MEDBOT-B (02252) has been raised from 30.9 Hong Kong dollars to 42 Hong Kong dollars. This valuation is based on cash flow discount rate, with an investment rating of "hold". It is reiterated that this stock is the preferred choice for China's medical technology stocks, and the stock price is considered a good buying opportunity as it has declined despite no change in fundamental factors. Siasun Robot & Automation's global order momentum remains strong, with over 170 sets of Siasun Robot & Automation orders accumulated by last Wednesday (8th), higher than the 150 sets at the end of August. The bank pointed out that Toumai (quadruple-lumen laparoscopic surgery Siasun Robot & Automation) is being installed globally, with rapid international expansion and applications in nearly 40 countries and major hospital systems, driving strong adoption. Based on approximately 100 sets of accumulated orders for Toumai, the bank has raised the forecast for this year's completion installation quantity from 84 sets to 105 sets, mainly due to overseas growth and the assumption that orders can be converted into sales within less than one quarter. The higher installation base and product portfolio improvements, as well as an expected improvement in gross profit margin of 1 to 1.5 percentage points.